Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer
- First Posted Date
- 2003-12-17
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 36
- Registration Number
- NCT00005646
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸State University of New York - Upstate Medical University, Syracuse, New York, United States
🇺🇸Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States
Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT00003927
- Locations
- 🇺🇸
Cancer Center and Beckman Research Institute, City of Hope, Duarte, California, United States
Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery
- Conditions
- Interventions
- First Posted Date
- 2003-11-26
- Last Posted Date
- 2016-07-20
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 366
- Registration Number
- NCT00003387
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States
🇺🇸University of California San Diego Cancer Center, La Jolla, California, United States
Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2003-11-26
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Oncotech
- Target Recruit Count
- 100
- Registration Number
- NCT00003253
- Locations
- 🇺🇸
Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, California, United States
🇺🇸Palmetto Hematology/Oncology Associates, Spartanburg, South Carolina, United States
🇺🇸Chao Family Comprehensive Cancer Center, Orange, California, United States
Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer
- First Posted Date
- 2003-11-26
- Last Posted Date
- 2014-11-21
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 243
- Registration Number
- NCT00003313
- Locations
- 🇺🇸
North Mississippi Medical Center/Cancer Center, Tupelo, Mississippi, United States
🇺🇸RMH Regional Canter Center, Harrisonburg, Virginia, United States
🇺🇸Greater Baltimore Medical Center and Cancer Center, Baltimore, Maryland, United States
Paclitaxel in Treating Women With Recurrent Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-11-25
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 32
- Registration Number
- NCT00003130
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
- Conditions
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2013-03-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00072319
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1
- Registration Number
- NCT00072215
- Locations
- 🇺🇸
Broward General Medical Center, Fort Lauderdale, Florida, United States
🇺🇸Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸Palm Beach Cancer Institute - West Palm Beach, West Palm Beach, Florida, United States
Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer
- Conditions
- First Posted Date
- 2003-11-04
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00005046
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-11-04
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 36
- Registration Number
- NCT00004093
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.